> ## Content Index
> Fetch the complete content index at: https://acentricresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biotechnology × Quantum: Intersection Brief – November 2026
- URL: https://acentricresearch.com/research/biotechnology-quantum-brief-2026-11/
- Published: 2026-11-20T21:44:25.000Z
- Updated: 2026-11-20T21:44:25.000Z
- Author: Kevin Meyer
- Tags: intersection-brief, biotechnology-quantum

> Acentric Research is produced with AI tools under human review. It is affiliated with Acentric Capital, a private investment group whose members may hold positions in companies discussed. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in [Biotechnology × Quantum in the Landscape Report](https://acentricresearch.com/research/landscape-2026-11/#biotechnology-quantum).

### Overview

Quantum technology uses the behavior of atoms and light at very small scales. Two uses matter for health. Quantum sensors measure extremely weak signals, such as the magnetic field made by electrical activity in the brain or heart. Quantum computers aim to calculate how molecules behave, which could help design drugs. Biotechnology here means anything biological or medical that affects people.

The sources opened show a gap between the two, and the pair has three Junctions: one about sensing the brain and heart, one about diamond sensors for biology, and one about computing for drug discovery. Sensing is further along: a heart-imaging system that its maker says uses optically pumped magnetometers (which the 2023 review calls quantum sensors) received an FDA 510(k) clearance in March 2019, and a company reports selling brain scanners that use them to research centres. \[1\]\[2\]\[3\] Computing for drug discovery is earlier: the sources describe funded studies and prize challenges, and the review abstract read says the calculations it studies need an error-corrected quantum architecture. \[4\]\[5\] The dated sources opened run from 2019 to 2026, and most are from 2019 to 2024; later developments in quantum computing for drug discovery and in diamond sensing were not searched.

### Current state

**What each technology does for the other.** Quantum physics gives biology new ways to measure and, in principle, to compute. A 2023 review focuses on two sensing platforms, optically pumped atomic magnetometers and nitrogen-vacancy centres in diamond, and says quantum sensors are finding their way from laboratories to the real world. \[6\] Biology supplies the test: a sensor must work on a living person or in a cell, and a calculation must help find a medicine.

**Who is working on it.** In the United States, the National Institutes of Health (NIH) runs a quantum computing program through its Office of Data Science Strategy, and the National Center for Advancing Translational Sciences runs prize challenges in quantum sensing and quantum computing. \[7\]\[5\] In the United Kingdom, the national quantum technologies programme describes work on wearable brain scanning and on quantum computing for health care. \[8\] The same programme describes a third area, quantum imaging, in which a UK hub is working with a semiconductor maker on a pulse oximeter that uses the travel time of light to remove patient-specific calibration, and on imaging through tissue with light; it reported that first results were due later in 2022 (programme statement, not checked against results). \[8\] Companies are described below in the words of the sources that name them.

**Three Junctions.**

- **Quantum magnetometry for brain and heart imaging.** Sensors that read magnetic fields from the brain or heart without supercooling. A heart-imaging system has an FDA 510(k) clearance; brain systems are in research use. See the [Junction Brief](https://acentricresearch.com/research/quantum-magnetometry-brain-heart-brief-2026-11/). \[1\]\[3\]
- **Diamond quantum sensing for biology and diagnostics.** Sensors built on defects in diamond. The company sources opened describe medical imaging as one of several targets, not a product. See the [Junction Brief](https://acentricresearch.com/research/diamond-quantum-sensing-biology-brief-2026-11/). \[9\]
- **Quantum computing for drug discovery and biology.** Quantum calculations of molecules. Funded projects exist; the sources opened report no result that beats conventional computing. See the [Junction Brief](https://acentricresearch.com/research/quantum-computing-drug-discovery-brief-2026-11/). \[10\]\[4\]

**What was left out.** One area was considered and excluded: security and blockchain for health data, a general use of the technology rather than a change to biotechnology. No three-realm candidate was flagged for this pair. \[11\]

**How far it has come.** The pair spans very different stages, and the Junction Briefs give the detail. A heart-imaging system whose maker says it uses optically pumped magnetometers was cleared in the United States in 2019; quantum brain imaging is sold for research and, per its maker, is moving through clinical approval; diamond sensing, as seen in the one start-up found, is at an early stage; quantum drug-discovery computing is in funded research and planning. \[1\]\[3\]\[9\]\[10\]

### Opportunities

Sensors that need no supercooling could lower cost, as the UK programme says of installation and running costs for wearable MEG; the OPM-MEG review abstract lists better data quality, adaptability to any head size, motion robustness and no reliance on cryogenics as the potential gains. \[12\] For computing, the Blunt and colleagues perspective estimates that recent algorithm advances cut the resources needed for a drug-relevant calculation from over 1,000 years to a few days on an error-corrected machine. \[4\]

### Challenges

- **Physics and engineering.** The computing estimates assume an error-corrected quantum architecture, which the abstract describes. \[4\] NCATS says use of quantum sensing in biomedical fields “remains narrow and not well explored” and needs further optimization, testing and validation. \[5\]
- **Regulation.** The sources opened show one FDA clearance in the pair, for heart imaging; a brain scanner maker reports progress through clinical approval pathways but states no clearance. \[1\]\[3\]
- **Capital and scale-up.** Company-reported funding rounds are: £3.8 million for the brain-scanner maker and about three-quarters of a million dollars for a diamond-sensor start-up. \[3\]\[9\] The computing projects found are awards of over £1 million to £6.85 million, announced between 2021 and 2024, and the sources opened report no outcome for the earliest, which planned a demonstration within 18 months. \[13\]\[10\]

### Data sources

- **FDA 510(k), De Novo and PMA databases**, for device clearances. \[14\]
- **NIH RePORTER**, for federal grants. \[15\]
- **ClinicalTrials.gov**, for studies of quantum-sensing devices. \[16\]
- **Europe PMC**, for the research literature. \[17\]
- No registry covers quantum-computing drug projects; funding announcements and company releases are the only record found.

### Changelog

- 2026-11-18: First published.

### Sources

1. openFDA 510(k) database, record K182571, “CardioFlux with Faraday Analytical Cloud”, Genetesis, Inc., decision date 2019-03-15, “Substantially Equivalent” (agency data, queried through the API; the device-name searches “magnetoencephalograph\*” and “MEG” returned no optically pumped magnetometer system, which is not proof of absence). [api.fda.gov](https://api.fda.gov/device/510k.json?search=device%5Fname:cardioflux&ref=acentricresearch.com) (accessed 2026-11-18)
2. MedTech Innovator, “Genetesis CardioFlux platform receives FDA 510(k) clearance”, 2019-03-22 (company announcement reproduced by an accelerator). [medtechinnovator.org](https://medtechinnovator.org/genetesis-cardioflux-platform-receives-fda-510k-clearance/?ref=acentricresearch.com) (accessed 2026-11-18)
3. The Quantum Insider, “Cerca Magnetics Secures £3.8M Series A Funding to Scale Quantum Brain Scanner”, 2026-04-21 (trade press reproducing a company press release; the sales, clinical-approval and growth statements are the company’s). [thequantuminsider.com](https://thequantuminsider.com/2026/04/21/cerca-magnetics-secures-38m-series-a-funding-scale-quantum-brain-scanner/?ref=acentricresearch.com) (accessed 2026-11-18)
4. Nicholas S. Blunt and others, “Perspective on the Current State-of-the-Art of Quantum Computing for Drug Discovery Applications”, Journal of Chemical Theory and Computation, 2022, abstract (Europe PMC record, PMID 36355616; the full text was not read). [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT%5FID:36355616%20AND%20SRC:MED&format=json&resultType=core&ref=acentricresearch.com) (accessed 2026-11-18)
5. National Center for Advancing Translational Sciences, “Quantum Research Activities” (agency page). [ncats.nih.gov](https://ncats.nih.gov/research/research-activities/quantum?ref=acentricresearch.com) (accessed 2026-11-18)
6. Nabeel Aslam and others, “Quantum sensors for biomedical applications”, Nature Reviews Physics, 2023, abstract (Europe PMC record, PMID 36776813; the full text was not read). [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT%5FID:36776813%20AND%20SRC:MED&format=json&resultType=core&ref=acentricresearch.com) (accessed 2026-11-18)
7. NIH Office of Data Science Strategy, “NIH/ODSS Quantum Computing Program” (agency page, last reviewed 2025-12-30). [datascience.nih.gov](https://datascience.nih.gov/tools-and-analytics/nihodss-quantum-computing-program-advancing-biomedical-research-through-quantum-innovation?ref=acentricresearch.com) (accessed 2026-11-18)
8. UK National Quantum Technologies Programme, “Four ways quantum technologies are advancing the future of healthcare”, 2022-05-24 (programme statement). [uknqt.ukri.org](https://uknqt.ukri.org/news/four-ways-quantum-technologies-are-advancing-the-future-of-healthcare?ref=acentricresearch.com) (accessed 2026-11-18)
9. University of Sydney, “Sydney spinout Deteqt secures backing for diamond-on-silicon sensing tech”, 2025-03-31 (university news release relaying company statements). [sydney.edu.au](https://www.sydney.edu.au/news-opinion/news/2025/03/31/sydney-spinout-deteqt-secures-backing-for-diamond-on-silicon-sen.html?ref=acentricresearch.com) (accessed 2026-11-18)
10. The Quantum Insider, “University of Nottingham, Phasecraft and QuEra Awarded £1 Million for Drug Development Research”, 2024-04-13 (trade press reproducing a university press release). [thequantuminsider.com](https://thequantuminsider.com/2024/04/13/university-of-nottingham-phasecraft-and-quera-awarded-1-million-for-drug-development-research/?ref=acentricresearch.com)(accessed 2026-11-18)
11. Acentric Research, “Landscape Report, November 2026”, exclusions and three-realm candidates. [acentricresearch.com](https://acentricresearch.com/research/landscape-2026-11/#exclusions) (accessed 2026-11-18)
12. Matthew J. Brookes and others, “Magnetoencephalography with optically pumped magnetometers (OPM-MEG): the next generation of functional neuroimaging”, Trends in Neurosciences, 2022, abstract (Europe PMC record, PMID 35779970; the full text was not read). [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT%5FID:35779970%20AND%20SRC:MED&format=json&resultType=core&ref=acentricresearch.com) (accessed 2026-11-18)
13. The Quantum Insider, “SEEQC UK Awarded £6.8M Innovate UK Grant to Build Enterprise-Level Quantum Enhanced Computer for Pharmaceutical R&D”, 2021-11-05 (trade press reproducing a company press release; plans and claims are the company’s). [thequantuminsider.com](https://thequantuminsider.com/2021/11/05/seeqc-uk-awarded-6-8m-innovate-uk-grant-to-build-enterprise-level-quantum-enhanced-computer-for-pharmaceutical-rd/?ref=acentricresearch.com) (accessed 2026-11-18)
14. FDA 510(k), De Novo and PMA databases. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ref=acentricresearch.com) (listed as a data source; the 510(k) record cited was read through openFDA)
15. NIH RePORTER, project search. [reporter.nih.gov](https://reporter.nih.gov/?ref=acentricresearch.com) (listed as a data source, not opened for this Brief)
16. ClinicalTrials.gov, study search. [clinicaltrials.gov](https://clinicaltrials.gov/?ref=acentricresearch.com) (listed as a data source; not searched for this Brief)
17. Europe PMC REST API. [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22quantum%20sensing%22&format=json&ref=acentricresearch.com) (listed as a data source; review abstracts were read through it for other claims in this Brief, 2026-11-18; not searched for this Junction)